Shariat - Figure 46
Recurrences after BCG
FIG. 46: Determining recurrence sanctuary sites after BCG treatment is also essential in the management of T1 high-grade bladder cancer. These sites could be submucosal or, as shown by the Memorial Sloan Kettering Cancer Center group (Figure), within 15 years could be in the upper tract in 40% of the patients or in the prostate.[53] In patients who have been treated with BCG I often survey the upper tract with cytology or selective cytology and imaging. A specimen from the prostatic urethra or of abnormal areas will help identify those patients who have disease recurrence in sanctuary sites, such as the prostate.
References
Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol. 1999;161:1854−7 http://dx.doi.org/10.1016/S0022-5347(05)68826-X
